Dailey H A, Dailey T A
Department of Microbiology, University of Georgia, Athens 30602-2605, USA.
Cell Mol Biol (Noisy-le-grand). 1997 Feb;43(1):67-73.
Protoporphyrinogen oxidase (E.C.1.3.3.4) (PPO) catalyzes the penultimate step in the heme biosynthetic pathway. Deficiency in activity of this enzyme results in the human genetic disease variegate porphyria. Herein we detail the cloning, expression, purification and characterization of the normal and variegate porphyria forms of human PPO. The cDNA sequence for human ppo is approximately 1.8 kb in length and codes for a protein of 477 amino acids. This protein, which does not contain a typical cleavable mitochondrial targeting sequence, is approximately 51 kDa and contains a putative dinucleotide binding motif near the amino terminus. The active enzyme is a homodimer and contains an FAD. Attachment of a six his amino terminal tag allows for the rapid and efficient purification of approximately 10 mg of enzyme from one liter of E. coli culture. Three variegate porphyria mutant PPO enzymes were expressed and characterized. These mutations, R59W, R168C and A433P, result in decreased enzyme activity by causing a decrease in kcat without a significant change in Km for the substrate protoporphyrinogen IX. Purified R59W lacks the FAD cofactor which may be explained by the fact that this mutation resides within the dinucleotide binding motif of PPO.
原卟啉原氧化酶(E.C.1.3.3.4)(PPO)催化血红素生物合成途径中的倒数第二步。该酶活性缺乏会导致人类遗传性疾病杂合性卟啉症。在此我们详细阐述了人PPO正常形式和杂合性卟啉症形式的克隆、表达、纯化及特性。人ppo的cDNA序列长度约为1.8 kb,编码一个477个氨基酸的蛋白质。该蛋白质不含典型的可裂解线粒体靶向序列,分子量约为51 kDa,在氨基末端附近含有一个假定的二核苷酸结合基序。活性酶是一个同型二聚体,含有一个FAD。在氨基末端连接六个组氨酸标签可从一升大肠杆菌培养物中快速高效地纯化出约10 mg的酶。表达并鉴定了三种杂合性卟啉症突变PPO酶。这些突变,即R59W、R168C和A433P,通过导致催化常数(kcat)降低而酶活性下降,而对底物原卟啉原IX的米氏常数(Km)没有显著变化。纯化的R59W缺乏FAD辅因子,这可能是因为该突变位于PPO的二核苷酸结合基序内。